menu
    • menu

    Company profile for AlzeCure Pharma

    NEW Drugs in Dev: 6
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and prev...
    AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AlzeCure PharmaSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Hälsovägen 7, SE-141 57 Huddinge
    Telephone
    Telephone
    559094-8302.
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.alzecurepharma.se/en/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alzecure Publishes Its Interim Report For January – March 2026
    Alzecure Publishes Its Interim Report For January – March 2026

    05 May 2026

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/alzecure-publishes-its-interim-report-for-january-%e2%80%93-march-2026-1163799

    ACCESSWIRE
    05 May 2026
    Share Share
    Adjusted Timeline for the Previously Communicated Rights Issue
    Adjusted Timeline for the Previously Communicated Rights Issue

    30 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-30/adjusted-timeline-for-the-previously-communicated-rights-issue

    PHARMIWEB
    30 Apr 2026
    Share Share
    Alzecure Pharma Publishes Its Annual Report For 2025
    Alzecure Pharma Publishes Its Annual Report For 2025

    08 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-08/alzecure-pharma-publishes-its-annual-report-for-2025

    PHARMIWEB
    08 Apr 2026
    Share Share
    Alzecure Pharma To Present At Redeye Healthcare Day On April 14
    Alzecure Pharma To Present At Redeye Healthcare Day On April 14

    07 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-07/alzecure-pharma-to-present-at-redeye-healthcare-day-on-april-14

    PHARMIWEB
    07 Apr 2026
    Share Share
    AlzeCure Pharma to Present at Redeye Alzheimer's Event Apr 9
    AlzeCure Pharma to Present at Redeye Alzheimer's Event Apr 9

    01 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-01/alzecure-pharma-to-present-at-redeye-alzheimers-theme-event-on-april-9

    PHARMIWEB
    01 Apr 2026
    Share Share
    AlzeCure Unveils Neurorestore ACD856 Data At AD/PD Conference
    AlzeCure Unveils Neurorestore ACD856 Data At AD/PD Conference

    19 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-19/alzecure-presents-new-preclinical-data-with-neurorestore-acd856-at-the-alzheimers-conference-adpd-1

    PHARMIWEB
    19 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search